NEUROCRINE BIOSCIENCES INC Debt Securities, Available-for-sale
NEUROCRINE BIOSCIENCES INC (NBIX) had Debt Securities, Available-for-sale of $857.90 million as of 2019-12-31, per its 10-K filed 2020-02-07.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2020-02-07
- 2019-12-31: Debt Securities, Available-for-sale $857.90M.
- 2019-06-30: Debt Securities, Available-for-sale $702.86M.
- 2019-03-31: Debt Securities, Available-for-sale $684.38M.
- 2018-12-31: Debt Securities, Available-for-sale $725.23M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2019-12-31 | $857.90M 10-K · filed 2020-02-07 |
| 2019-06-30 | $702.86M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $684.38M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $725.23M 10-K · filed 2020-02-07 |
| 2017-12-31 | $508.58M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |